Although information has accumulated regarding the nature of tyrosinase and its role in melanin pigmentation, very little is known as to why there is almost complete absence of melanization in the melanosome of amelanotic malignant melanoma whereas the reverse is true of melanotic malignant melanoma.
In 1946 Rothman and co-workers postulated that the natural regulation of melanin formnation may depend upon organic sulfhydryl compound inhibition of tyrosinase, and demonstrated an inhibitory factor in human epidermis which could be released by specific sulfhydryl poisons (1) . Similar studies were reported by Flesch in 1949 (2) . Riley (3) and Hirsch (4) reported an inhibitor of dopa oxidase activity in mouse melanoma. Identification and characterization of such inhibitors has not been well defined.
The following is a report of a preliminary study of tyrosinase inhibitor found in amelanotic and melanotic malignant melanoma of the Syrian golden hamster.
METHODS AND MATERIALS
Fortner's amelanotic malignant melanoma type 3 and Fortner's melanotic malignant melanoma O.25M sucrose-0.02M phosphate buffer using a Teflon head hand homogenizer, centrifuged at 700 X g to remove cell debri and then centrifuged at 12,000 X g to obtain a soluble fraction. Temperatures were maintained at 2°C. during this preparation. All tumors were so processed unless otherwise specified.
Studies of tyrosinase enzyme kinetics were ing L-dopa as substrate and crystallized mushroom tyrosinase as enzyme source. The linear portion of mushroom tyrosinase from 30 seconds to 1 minute and 30 seconds was used, during which time interval no enzyme activity was contributed by melanotic fraction since the lag phase of melanotic fraction was at least 5 minutes. Fig. 2 indicates that the percent of inhibition of mushroom tyrosinase by amelanotic melanoma fraction is considerably greater than that of melanotic melanoma, there being 18% inhibition by amelanotic fraction as compared to 11% by melanotic for 0.04 g melanoma respectively, 29% by amelanotic compared to 13% by melanotic for 0.08 g melanoma respectively, and 37% by amelanotic as compared with 17% by melanotic for 0.12 g melanoma. Therefore, although inhibitor effect is demonstrated by melanotic melanoma, the inhibition is significantly more pronounced in amelanotic melanoma.
In order to study further the properties of this inhibitor, melanomas were homogenized in 0.02 M phosphate buffer and a 12,000 x g soluble fraction prepared. These fractions were dialyzed against distilled water at pH 7.0 overnight. The diffusates were flash-evaporated and then tested for their inhibitory effect on mushroom tyrosinase. Fig. 3 shows that both melanotic and amclanotic diffusate equiv- alent to 0.04 g, 0.08 g, and 0.1 g original melanoma had quite similar inhibitory effeet; therefore, 0.04 g had 33% inhibition, 0.08 g had 43% inhibition, and 0.1 g had 45% inhibition. The dialysate had no inhibitory effect toward mushroom tyrosinase or melanoma soluble fractions. Furthermore, the inhibitor from melanotic melanoma appears to be bound as its inhibitory effect is much less than that exhibited by amelanotic melanoma whereas after dialysis the inhibitor from both melanomas exerts very similar inhibitory ci. In summary, the following properties are attributed to inhibitor obtained by dialysis of 12,000 x g homogenates of both melanotic and 4. Inhibitory effect on mushroom tyrosinase unchanged by addition of Cn2, therefore this substance appears not to be a sulfhydryl compound.
5. Kinetic studies reveal the inhibitors to be competitive.
Using mushroom tyrosinasc as an enzyme source, the Michaelis-Menten constant of mushroom tyrosinase was found to be 3.3 >< 10-4M, the K, of melanotic inhibitor 5.5 x 104M, and the K, of amelanotic inhibitor 4.2 x 104M. The K1 value of mushroom tyrosinase was close to that found for tyrosinase from melanotic melanoma.
Further studies arc now in progress to isolate and identify these inhibitors.
CONCLUSION5
The defects in melanogenesis in amelanotie melanoma may be attributed in part to disturbed tyrosinase synthesis and the presence of inhibitors since melanosome formation (6) and active tyrosine release utilizable as substrate bas been shown in amelanotic melanoma (7).
Fortner's amelanotic melanoma type 3 exhibited no tyrosinase activity in 20 cases presently studied. Furthermore, removing inhibitor from amelanotic fractions by dialysis failed to reveal tyrosinase activity.
The characteristic properties of inhibitor found in both melanotic and amelanotic melanoma arc heat stability, dialyzable, not a sulfhydryl compound, and competitive inhibition.
